# A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

> **NCT06389526** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Coherus Oncology, Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** CHS-1000
- **BIOLOGICAL:** Toripalimab

## Key facts

- **NCT ID:** NCT06389526
- **Lead sponsor:** Coherus Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2028-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06389526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06389526, "A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06389526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*